Cite

    Bojer, A. et al. (2021). Metabolic improvement with short‐term, glucagon‐like peptide‐1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial. Diabetes, obesity & metabolism. 23 (10), pp. 2374-2384. [Online].